Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily”In the company’s words, NCT03070951 on ClinicalTrials.gov
- Tested for
- Uterine Fibroids (2 trials), Heavy Menstrual Bleeding (2 trials)
- Main trialPhase 3
- “The primary objective of this study is to demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.”In the company’s words, NCT03070951 on ClinicalTrials.gov
Other drugs for Uterine Fibroids
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 16 Sep 2019 | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids | |
| Phase 3Completed | 14 Apr 2020 | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026